{"id":768553,"date":"2023-07-10T10:29:16","date_gmt":"2023-07-10T14:29:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/"},"modified":"2023-07-10T10:29:16","modified_gmt":"2023-07-10T14:29:16","slug":"maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/","title":{"rendered":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies"},"content":{"rendered":"

\nMaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform will support Vittoria\u2019s Senza5\u2122 technology to enhance efficacy and improve clinical utility of T-cell therapies.
\n<\/h2>\n
\n

ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc.<\/a>, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics<\/a> (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to Vittoria Biotherapeutics.<\/p>\n

Under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.<\/p>\n

Vittoria\u2019s technology and clinical programs are designed to address current gaps with contemporary cell therapies and the Company is planning to file an investigational new drug application (IND) for their lead program, Viper 101, later this year. Viper 101 is a gene-edited, autologous, dual-population cell therapy developed from Vittoria\u2019s proprietary Senza5\u2122 platform that addresses significant unmet therapeutic need for the treatment of T-cell lymphoma.\u00a0Vittoria\u2019s patent-protected Senza5\u2122 platform technology is designed to improve the viability, efficacy, and safety of CAR-T treatments by modulating a novel checkpoint pathway in engineered T-cells. Senza5\u2122 CAR-T cells have demonstrated superior anti-tumor efficacy in both liquid and solid tumor preclinical models and utilize a proprietary five-day manufacturing process.<\/p>\n

\u201cWorking with partners to produce best-in-class solutions that accelerate the development of novel therapies to improve patient outcomes is central to our company\u2019s mission\u201d said Doug Doerfler, President and Chief Executive Officer of MaxCyte.<\/strong> \u201cThrough our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies. We look forward to supporting Vittoria\u2019s efforts to improve efficacy and enhance safety of T-cell therapies.\u201d<\/p>\n

\u201cAt Vittoria, our goal is to deliver next-generation T-cell therapies designed to improve patient outcomes\u00a0by enhancing the overall clinical utility and safety of engineered cell therapies,\u201d said Nicholas Siciliano, Ph.D., Chief Executive Officer of Vittoria<\/strong>. \u201cMaxCyte’s experience with clinical grade manufacturing of gene-edited cellular therapeutics will greatly enhance the robustness and reproducibility of our manufacturing process, ensuring that each batch of our CAR-T cells meets the highest standards of consistency and quality. This is an important step forward as we work to develop the next generation of cellular therapies to benefit patients.\u201d<\/p>\n

MaxCyte\u2019s ExPERT\u2122 instrument portfolio is the next generation of leading, clinically validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT\u2122 platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Vittoria is MaxCyte\u2019s 22nd<\/sup> SPL overall.<\/p>\n

\n About MaxCyte<\/strong>\n <\/p>\n

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients\u2019 lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today\u2019s processes to innovate tomorrow\u2019s solutions. Our ExPERT\u2122 platform, which is based on our Flow Electroporation\u00ae<\/em> technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx\u2122, STx\u2122, GTx\u2122 and VLx \u2122; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n About Vittoria Biotherapeutics<\/strong>\n <\/p>\n

Vittoria Biotherapeutics, Inc. (https:\/\/vittoriabio.com<\/a>) is a leading edge, gene-edited cell therapy company with novel platform technologies exclusively licensed from the University of Pennsylvania. Vittoria\u2019s technology and clinical programs are designed to address current gaps with contemporary cell therapies and its pipeline benefits from access to novel gene editing technologies. The Company is on track to file an IND in mid-2023 for their lead program, Viper 101. Viper 101 is a gene-edited, autologous, dual-population cell therapy that addresses a significant unmet therapeutic need for the treatment of T-cell lymphoma. Vittoria\u2019s gene-edited platform technology has demonstrated superior anti-tumor efficacy in both liquid and solid tumor preclinical models and utilizes a proprietary \u201cshort\u201d (5-day) manufacturing process. To learn more, visit vittoriabio.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

\n MaxCyte Contacts:<\/strong>\n <\/p>\n\n\n\n
\n
\n US IR Adviser<\/em>
\n <\/strong>
\n
\n
\n Gilmartin Group<\/em>
\n <\/strong>
\n
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com<\/a><\/p>\n<\/td>\n		\n
\n US Media Relations<\/em>
\n <\/strong>
\n
\n
\n Spectrum Seismic Collaborative<\/em>
\n <\/strong>
\n
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com<\/a><\/p>\n<\/td>\n<\/tr>\n
\n
\n Nominated Adviser and Joint Corporate Broker<\/em>
\n <\/strong>
\n
\n Panmure Gordon<\/strong>
\n
Emma Earl \/ Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500<\/p>\n<\/td>\n		\n
\n UK IR Adviser<\/em>
\n <\/strong>
\n
\n
\n Consilium Strategic Communications<\/em>
\n <\/strong>
\n
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n Vittoria Contacts:<\/strong>\n <\/p>\n

\u00a0<\/p>\n\n\n\n\n\n\n\n
\n
\n Investor Contact<\/strong>
\n <\/em>\n <\/td>\n		\n \u00a0Media Relations<\/em><\/strong>\n <\/td>\n<\/tr>\n
\n
\n Vittoria Biotherapeutics<\/strong>
\n <\/em>\n <\/td>\n		\n
\n LifeSci Communications<\/strong>
\n <\/em>\n <\/td>\n<\/tr>\n
Nicholas A. Siciliano, Ph.D.<\/td>\nMichael Tattory<\/td>\n<\/tr>\n
Chief Executive Officer<\/td>\n+1 609-802-6265<\/td>\n<\/tr>\n
+1 215-600-1380<\/td>\n\n mtattory@lifescicomms.com<\/a>\n <\/td>\n<\/tr>\n
\n nsiciliano@vittoriabio.com<\/a>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform will support Vittoria\u2019s Senza5\u2122 technology to enhance efficacy and improve clinical utility of T-cell therapies. ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to Vittoria Biotherapeutics. Under the terms of … <\/p>\n

Continue reading “MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768553","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform will support Vittoria\u2019s Senza5\u2122 technology to enhance efficacy and improve clinical utility of T-cell therapies. ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to Vittoria Biotherapeutics. Under the terms of … Continue reading "MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T14:29:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies\",\"datePublished\":\"2023-07-10T14:29:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/\"},\"wordCount\":898,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/\",\"name\":\"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=\",\"datePublished\":\"2023-07-10T14:29:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies - Market Newsdesk","og_description":"MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform will support Vittoria\u2019s Senza5\u2122 technology to enhance efficacy and improve clinical utility of T-cell therapies. ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to Vittoria Biotherapeutics. Under the terms of … Continue reading \"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-10T14:29:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies","datePublished":"2023-07-10T14:29:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/"},"wordCount":898,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/","name":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=","datePublished":"2023-07-10T14:29:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTU1NCM1NjgyNTk0IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-and-vittoria-biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768553"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768553\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}